Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 3/20 | 0.52 |
| ▸ | XIAP | P98170 | 10/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4218830 | 0.77 | RIPK1 (0.63) | SCN9AMMEACEXIAPRIPK1 | |
| SCHEMBL3924251 | 0.77 | RIPK1 (0.63) | SCN9AMMEACEXIAPRIPK1 | |
| SCHEMBL14376829 | 0.77 | RIPK1 (0.60) | SCN9AMMEACEXIAPRIPK1 | |
| SCHEMBL13875790 | 0.76 | PSEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3287904 | 0.76 | NOTCH1 (0.53) | SCN9AMMEACEXIAPRIPK1 | |
| SCHEMBL5948015 | 0.76 | NOTCH1 (0.53) | SCN9AMMEACEXIAPRIPK1 | |
| SCHEMBL13875787 | 0.73 | MMP1 (0.43) | MMEACEXIAP | |
| SCHEMBL8670502 | 0.73 | SCN9A (0.55) | SCN9AMMEACEXIAPRIPK1 | |
| SCHEMBL8665579 | 0.73 | AGTR1 (0.55) | SCN9AMMEACEXIAPRIPK1 | |
| SCHEMBL4985420 | 0.72 | PSEN1 (0.63) | SCN9AXIAPPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | SCN9A 84/4885MME 486/4885ACE 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.